Therefore, TCbHP has become the first-line regimen of dual target NAT for HER2-positive BC, as recommended by the National Comprehensive Cancer Network (NCCN) and Chinese Society of Clinical Oncology (CSCO) guidelines (10–12). This evidence concerns the gene ERBB2 and breast cancer.